Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
10,001 - 25,000 - Monthly Reach
Unique listeners across all episodes (30 days)
25,001 - 75,000 - Active Followers
Loyal subscribers who consistently listen
15,001 - 40,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 14 epsHost
Recent guests
No guests detected in recent episodes.
Recent episodes
Pfizer's $300M Biologics Boost & FDA's Veppanu Approval | Pharma and Biotech Daily
May 5, 2026
4m 47s
AstraZeneca's $5B Setback: FDA Rejects New Cancer Drug | Pharma and Biotech Daily
May 4, 2026
5m 46s
Novartis' $23B U.S. Investment Boosts Pharma Manufacturing | Pharma and Biotech Daily
May 1, 2026
5m 54s
AstraZeneca's £300M UK Investment Resumes Amid FDA Pilot | Pharma and Biotech Daily
Apr 30, 2026
4m 42s
AstraZeneca's Breztri Asthma Approval Boosts $80B Goal | Pharma and Biotech Daily
Apr 29, 2026
5m 33s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 5/5/26 |  Pfizer's $300M Biologics Boost & FDA's Veppanu Approval | Pharma and Biotech Daily | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant updates that highlight the dynamic nature of our industry, driven by cutting-edge science, regulatory evolution, and strategic business innovations. The pharmaceutical landscape is ever-shifting, with recent developments underscoring this fluidity. Pfizer and Arvinas have secured early FDA approval for their brea... | 4m 47s | ||||||
| 5/4/26 | AstraZeneca's $5B Setback: FDA Rejects New Cancer Drug | Pharma and Biotech Daily | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the transformative dynamics shaping the industry, from financial innovations to regulatory hurdles, each having profound implications for patients and stakeholders alike. The pharmaceutical and biotech industries are in the midst of a transformative period, grappling with the challenge of making advanced therapies, particularly cell and gen... | 5m 46s | ||||||
| 5/1/26 | Novartis' $23B U.S. Investment Boosts Pharma Manufacturing | Pharma and Biotech Daily✨ | pharmaceutical investmentbiotech advancements+3 | — | Novartis | U.S.Morrisville, North Carolina | Novartisinvestment+5 | — | 5m 54s | |
| 4/30/26 | AstraZeneca's £300M UK Investment Resumes Amid FDA Pilot | Pharma and Biotech Daily✨ | AstraZeneca investmentFDA initiatives+3 | — | AstraZenecaFDA | UK | AstraZenecaUK investment+4 | — | 4m 42s | |
| 4/29/26 | AstraZeneca's Breztri Asthma Approval Boosts $80B Goal | Pharma and Biotech Daily✨ | drug approvalsregulatory changes+3 | — | BreztriTavneos+3 | — | AstraZenecaBreztri+7 | — | 5m 33s | |
| 4/28/26 | Sun Pharma's $11.75B Organon Deal: Industry Shockwave | Pharma and Biotech Daily✨ | acquisitionpharmaceutical industry+3 | — | Sun PharmaOrganon | India | Sun PharmaOrganon+5 | — | 4m 59s | |
| 4/27/26 | Merck Unveils PD-1xVEGF Data, Delays Phase 3 Plans | Pharma and Biotech Daily✨ | cancer therapiesregulatory updates+4 | — | PD-1xVEGF bispecific antibodyMerck | non-small cell lung cancer | MerckPD-1xVEGF+5 | — | 4m 59s | |
| 4/24/26 | Regeneron Gene Therapy Approved by FDA: A Game-Changer! | Pharma and Biotech Daily✨ | gene therapyFDA approval+3 | — | OtarmeniRegeneron+2 | — | Regenerongene therapy+5 | — | 5m 15s | |
| 4/23/26 | Amneal's $1.1B Biosimilars Move & Merck's HIV Pill | Pharma and Biotech Daily✨ | biosimilarspharmaceutical acquisition+3 | — | HIV PillAmneal Pharmaceuticals+2 | — | AmnealKashiv+5 | — | 5m 00s | |
| 4/22/26 | Merck Welireg Fails, Roche Enspryng Shines in Trials | Pharma and Biotech Daily✨ | oncologydrug development+3 | — | WeliregEnspryng+2 | kidney cancer | MerckWelireg+5 | — | 4m 57s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 4/21/26 | Eli Lilly's $7B Kelonia Buy Boosts CAR-T Tech | Pharma and Biotech Daily✨ | drug developmentbiotech advancements+3 | — | NuvaxovidMNEXspike+4 | — | Eli LillyKelonia+6 | — | 5m 10s | |
| 4/20/26 | Kailera IPO Raises $625M for Obesity Drug | Pharma and Biotech Daily✨ | Kailera IPOobesity drug+3 | — | KaileraChina+4 | — | KaileraIPO+5 | — | 5m 19s | |
| 4/17/26 | Gene Therapy Setbacks and Strategic Shifts in Biotech✨ | gene therapybiotech+3 | — | botaretigene sparoparvovecJohnson & Johnson+1 | — | gene therapybiotech+5 | — | 4m 49s | |
| 4/16/26 | AI Integration and Regulatory Shifts in Pharma✨ | AI integrationpharmaceuticals+3 | — | NovartisAnthropic | — | AIpharma+4 | — | 6m 03s | |
| 4/15/26 | AI Integration, FDA Milestones, and Strategic Shifts: Navigating Pharma's Future✨ | AI IntegrationFDA Milestones+3 | — | TremfyaIcotyde+1 | — | pharmaceuticalbiotech+6 | — | 4m 23s | |
| 4/14/26 | Radiopharmaceuticals to CAR-T: Pharma's Cutting-Edge Advances✨ | radiopharmaceuticalsdrug development+3 | — | radiopharmaceuticalsRegeneron+1 | — | RegeneronTelix Pharmaceuticals+3 | — | 5m 10s | |
| 4/13/26 | Biopunk Revolution: Reshaping Biotech Innovation | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the transformative potential of biopunk and community labs that are reshaping the biotechnology landscape. The biopunk movement, inspired by the punk music ethos, advocates for a more accessible, nimble, and innovative biotech future through grassroots initiatives. Elliot Roth, a serial biotech founder and community lab advocate, is chal... | 5m 23s | ||||||
| 4/10/26 | Revolutionizing Pharma: Key Innovations and Strategic Shifts | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of exciting and transformative updates shaping our industry. Let’s begin with the departure of a significant figure in pharmaceutical advocacy. Steven Ubl's exit as CEO of PhRMA marks a noteworthy change after over a decade at the helm. His leadership has been pivotal in advocating for policies that support pharmaceutical innov... | 4m 50s | ||||||
| 4/9/26 | Navigating Breakthroughs: Pharma's Evolution in Innovation and Strategy | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of dynamic changes and strategic shifts reshaping these industries, driven by scientific advancements and regulatory updates. Let's start with Biogen, which recently resolved an investor lawsuit concerning its Alzheimer's drug, Aduhelm. Approved under controversial circumstances by the FDA, Aduhelm faced scrutiny for its efficacy a... | 4m 59s | ||||||
| 4/8/26 | FDA's New Agenda & Gilead's Oncology Leap | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant advancements and strategic moves shaping the ever-evolving landscape of drug development and patient care. The U.S. Food and Drug Administration, under Commissioner Marty Makary, is pursuing a comprehensive policy agenda as revealed in the fiscal year 2027 budget proposal to Congress. This agenda proposes a new c... | 4m 45s | ||||||
| 4/7/26 | Pharma's Future: Mergers, Innovation, and AI | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events reshaping the industry as we know it. The pharmaceutical and biotech sectors are currently experiencing an unprecedented surge in mergers and acquisitions. This wave of consolidation is exemplified by Neurocrine Biosciences' substantial $2.9 billion acquisition of Soleno Therapeutics, marking a milestone as... | 5m 22s | ||||||
| 4/6/26 | Navigating Biopharma's Strategic Shift: Key Developments | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the key changes shaping our industry, from a contraction in drug development pipelines to shifts in international trade policies, and what these might mean for the future of healthcare. Recent reports from Citeline indicate that for the first time in three decades, the R&D pipeline within biopharma is experiencing a contraction.... | 5m 02s | ||||||
| 4/3/26 | Immunotherapy Breakthroughs and Regulatory Shifts in Pharma | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of remarkable advancements and challenges shaping these dynamic sectors. AstraZeneca has reported promising results with an immunotherapy combination involving Imfinzi (durvalumab) and Imjudo (tremelimumab) for treating locoregional liver cancer. This combination has demonstrated a significant progression-free survival benefit, pot... | 5m 19s | ||||||
| 4/2/26 | Oral GLP-1 Breakthroughs and Strategic Biotech Shifts | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events shaping the industry, from groundbreaking drug approvals to strategic corporate maneuvers.Recently, the U.S. Food and Drug Administration (FDA) granted approval for Eli Lilly's new GLP-1 receptor agonist pill, Foundayoby, marking a significant milestone as it's the first new molecular entity to be cleare... | 4m 43s | ||||||
| 4/1/26 | Pharma Giants Transforming Through Strategic Acquisitions and AI | Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of noteworthy advancements and strategic movements shaping the future of drug development and patient care.The pharmaceutical industry is seeing a flurry of mergers and acquisitions, reflecting a strategic push to enhance therapeutic portfolios. Biogen's $5.6 billion acquisition of Apellis Pharmaceuticals emphasizes its ambition... | 4m 45s | ||||||
Showing 25 of 64
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Similar Audience Demographics
Podcasts that attract a similar listener profile
Chart Positions
16 placements across 16 markets.
Chart Positions
16 placements across 16 markets.